Released on October 29, 2018, this double-blind, placebo-controlled, Phase 2 pilot study found that psychotherapy assisted by the administration of 3,4-Methylenedioxymethamphetamine (MDMA) yielded significant symptom reductions in 28 participants diagnosed with PTSD from military service, sexual assault, and other causes. The researchers found that one month after their second day-long experimental session, 42.9% in the active-dose (100mg and 125mg) MDMA groups did not qualify for a diagnosis of PTSD, compared to 33.3% in the low-dose MDMA (40mg active placebo) group. ⠀⠀⠀⠀⠀⠀⠀⠀⠀
(Here’s where it gets good). Twelve months after the third active-dose session of MDMA-assisted psychotherapy, 76% no longer met the criteria for a PTSD diagnosis. The treatment was well-tolerated. If the findings are replicated in upcoming Phase 3 trials, MDMA-assisted psychotherapy will become an available treatment option for people suffering from treatment-resistant PTSD as early as 2021.